University of Delaware

Other

Northwestern University

Elcriton, Inc.

Eleftherios Papoutsakis and Stefan Gaida

Eleftherios Terry Papoutsakis

Robert Kyle Bennett

William Brian Whitaker

Alan Fast

Maciek Antoniewicz

Jacqueline Gonzalez

Vasiliki Falara

Sergios Nicolaou

Jinlin Jiang

Chen-Yuan Kao

Nicholas Richard Sandoval

Bryan Patrick Tracy

Ryan Senger

Alexander A Mitkas

Daniel Knox Mitchell

Christopher A Tomas

Marija Tesic

Jose Y Santiago

Kamil Charubin

Stefan Marcus Gaida

Mohab Ali Al-Hinai

Shawn William Jones

Dinesh Chanukya Indurthi

Syntrophic co-cultures containing at least two microorganisms, wherein (a) at least one of the microorganisms is a solventogen able to metabolize biomass to produce metabolic byproduct(s) therefrom, (b) at least one of the microorganisms is a microorganism different from the solventogen, wherein the microorganism different from the primary solventogen depends on the metabolites and/or the metabolism of the primary solventogen for survival and growth and is able to fix or metabolize the metabolic byproducts produced by the solventogen to produce metabolic byproduct(s) therefrom, and (c) the solventogen is able to metabolize the metabolic byproduct(s) produced by the microorganism different from the solventogen to produce further metabolic byproducts, such as liquid fuels and commodity chemicals, as well as methods for using these syntrophic co-cultures to produce such products via fermentation, are disclosed.

Syntrophic co-cultures and uses thereof

Applications in transfusion medicine requiring platelets, and hematopoietic stem-cell transplantations require either platelets or enhancement of in vivo platelet biogenesis. Gene therapy applications of hematopoietic stem and progenitor cells (HSPCs) require effective and specific modification of HSPCs by DNA, RNA or other biological molecules. Here we disclose methods for the generation, and modification of megakaryocytic microparticles (MkMPs), proplatelets, preplatelets, platelet-like particles and megakaryocyte extracellular vesicles, that can be used in the aforementioned transfusion and transplantation medicine applications and in gene therapy applications involving hematopoietic stem cells. The biological effects of modified or unmodified MkMPs have never been previously disclosed and thus, this invention claims all biological applications of MkMPs in in vivo therapeutic applications to produce various cells and cell parts, modify various target cells or deliver molecules including drugs to HSPCs and related cells.

Megakaryocytic particles and microparticles for in vivo hematopoietic cell and gene therapies

A non-naturally occurring microbe capable of growing in a medium comprising methanol is provided. The methanol contributes to a significant percentage (e.g., at least 40%) of the carbon source for the non-naturally occurring microbe, which expresses heterologous methanol dehydrogenase (MDH) and heterologous ribulose monophosphate (RuMP) pathway enzymes. Methods for producing liquid fuels and chemicals by the non-naturally occurring microbe and methods for preparing the non-naturally occurring microbe are also provided.

Synthetic methylotrophy to liquid fuels and chemicals

The present invention provides a non-naturally occurring microbe capable of growing in a medium comprising methanol, comprising a heterologous polynucleotide encoding a heterologous methanol dehydrogenase (MDH) derived from aorganism (Cor), wherein the MDH is expressed in the microbe, and wherein the MDH exhibits a Km of no more than 3 mM for methanol. Also provided are uses of the non-naturally occurring microbe for oxidizing methanol and producing a metabolite as well as the preparation of the non-naturally occurring microbe.

Synthetic methylotrophs

Applications in transfusion medicine requiring platelets, and hematopoietic stem-cell transplantations require either platelets or enhancement of in vivo platelet biogenesis. Gene therapy applications of hematopoietic stem and progenitor cells (HSPCs) require effective and specific modification of HSPCs by DNA, RNA or other biological molecules. Here we disclose methods for the generation, and modification of megakaryocytic microparticles (MkMPs) or microvesicles, that can be used in the aforementioned transfusion and transplantation medicine applications and in gene therapy applications involving hematopoietic stem cells. The biological effects of modified or unmodified MkMPs have never been previously disclosed and thus, this invention claims all biological applications of MkMPs in in vivo therapeutic applications or ex vivo applications to produce various cells and cell parts, modify various target cells or deliver molecules including drugs to HSPCs and related cells.

Megakaryocytic particles and microparticles for cell therapy and fate modification of stem and progenitor cells

Methods for enhancing single cross-over homologous recombination in gram positive bacteria are presented. These methods provide enhanced capability to genetically modify gram positive bacteria.

Methods and compositions for genetically manipulating clostridia and related bacteria with homologous recombination associated proteins

The present invention relates to a recombinantexhibiting a complex phenotype, comprising one or more RNA polymerase subunit genes, one or more functional genes, and, optionally, one or more transcription factors from a heterologous prokaryote. Also provided are methods for screening such a recombinant

Engineering complex microbial phenotypes with transcription enhancement

The present invention relates a recombinantexpressing one or more heterologous Wood-Ljungdahl (WL) genes. In particular, the recombinantproduces a metabolite at an increased level. The present invention also relates to a method for producing a metabolite by the recombinant

[object Object]

A genome-scale metabolic network reconstruction for(ATCC 824) was created using a new semi-automated reverse engineering algorithm. This invention includes algorithms and software that can reconstruct genome-scale metabolic networks for cell-types available through the Kyoto Encyclopedia of Genes and Genomes. This method can also be used to complete partial metabolic networks and cell signaling networks where adequate starting information base is available. The software may use a semi-automated approach which uses a priori knowledge of the cell-type from the user. Upon completion, the program output is a genome-scale stoichiometric matrix capable of cell growth in silico. The invention also includes methods for developing flux constraints and reducing the number of possible solutions to an under-determined system by applying specific proton flux states and identifying numerically-determined sub-systems. Although the model-building and analysis tools described in this invention were initially applied to, the novel algorithms and software can be applied universally.

Reverse engineering genome-scale metabolic network reconstructions for organisms with incomplete genome annotation and developing constraints using proton flux states and numerically-determined sub-systems

Recombinant microorganisms and related methods of use to enhance tolerance to toxic substances. In particular, such microorganisms and methods can be used to increase solvent production.

Growing community of inventors

Newark, DE, United States of America

Eleftherios Terry Papoutsakis